CTKBCytek BioSciences Inc
CTKB
Cytek BioSciences Inc299
Mkt Cap
$511.4MVolume
392,646.0052W High
$6.1852W Low
$2.37PE Ratio
-6.86CTKB Fundamentals
Price
$3.99Prev Close
$3.96Open
$3.9850D MA
$4.38Beta
1.33Avg. Volume
555,570.02EPS (Annual)
-$0.5209P/B
1.56Rev/Employee
$287,847.14$416.61
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -50.00% and +0.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Cytek Biosciences (CTKB) Expected to Announce Earnings on Thursday
Cytek Biosciences (NASDAQ:CTKB) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-cytek-biosciences-inc-stock...
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives Average Recommendation of "Hold" from Analysts
Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) have been assigned an average rating of "Hold" from the six ratings firms that are covering the stock, Marketbeat.com reports. Two...
249,812 Shares in Cytek Biosciences, Inc. $CTKB Purchased by Tudor Investment Corp ET AL
Tudor Investment Corp ET AL bought a new position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 249,812 shares of the company's stock, valued at a...
Tudor Investment Corp ET AL Invests $867,000 in Cytek Biosciences, Inc. $CTKB
Tudor Investment Corp ET AL purchased a new stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) during the third quarter, according to the company in its most recent 13F filing...
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives Consensus Recommendation of "Hold" from Brokerages
Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) have received a consensus recommendation of "Hold" from the six analysts that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have given a hold rati...
Topline Capital Management LLC Has $24.10 Million Position in Cytek Biosciences, Inc. $CTKB
Topline Capital Management LLC raised its stake in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 32.7% in the third quarter, according to the company in its most recent filing with the...
Cytek Biosciences Highlights Aurora Evo, Recurring Revenue Growth and 2026 Outlook at TD Cowen Conference
Cytek Biosciences (NASDAQ:CTKB) outlined its recent product launches, geographic diversification, and expectations for 2026 during a presentation and fireside chat at TD Cowen's 42nd annual...
Royce & Associates LP Increases Holdings in Cytek Biosciences, Inc. $CTKB
Royce & Associates LP boosted its holdings in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 26.9% during the 3rd quarter, according to the company in its most recent 13F filing...
Cytek Biosciences, Inc. (NASDAQ:CTKB) Given Consensus Rating of "Hold" by Brokerages
Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) have earned an average recommendation of "Hold" from the seven analysts that are presently covering the company, Marketbeat.com...
<
1
2
...
>
Compact View
Not available
Not available